German biotechnology company BioNTech SE approached Southern Research to test the efficacy of their prophylactic (mRNA vaccine) against highly pathogenic MPXV Zaire strain in non-human primates (NHPs).
Describes preclinical testing of BioNTech’s MPXV vaccine, highlighting robust efficacy and safety data in non-human primate models.
Therapeutic Areas:
IDR
Capabilities:
Animal Models
Related Resources
Related Resource block to be added later.
Ready to Advance Your Research?
Contact our experts today and explore how Southern Research can elevate your project.